The aim of the SYMPLIFY study in Oxford is to demonstrate how the test could be used to increase cancer detection rates and simplify diagnostic pathways. Results of the Galleri tests will then be used for test validation purposes. Galleri is a blood test that can detect over 50 types of cancers — over 47 of which lack recommended screening in the UK today — with a low false positive rate of less than 1 percent, all through a single blood draw. Using revolutionary next-generation sequencing technology, Galleri has the potential to complement existing screening programmes and current tests to enhance early stage diagnosis, when cancers can be treated more successfully. Often this happens after a patient presents with symptoms and a cancer is more progressed.
